Scarica l'app Stockscreener
36.01
0.33%
-0.12
Dopo l'orario di chiusura:
35.99
-0.02
-0.06%
Agios Pharmaceuticals Inc Borsa (AGIO) Ultime notizie
Agios Pharmaceuticals Inc.’s volatility index tracking explainedWeekly Gains Report & Weekly Setup with High ROI Potential - Newser
Statistical indicators supporting Agios Pharmaceuticals Inc.’s strengthJuly 2025 WrapUp & Free Daily Entry Point Trade Alerts - Newser
Is Agios Pharmaceuticals Inc. backed by strong institutional buyingQuarterly Portfolio Report & Safe Capital Growth Trade Ideas - خودرو بانک
What is Agios Pharmaceuticals Inc.’s market positionJuly 2025 Outlook & Weekly Watchlist for Consistent Profits - خودرو بانک
Liver Injury REMS Delays US FDA Approval Of Agios’s Pyrukynd In Thalassemia - insights.citeline.com
Will Agios Pharmaceuticals Inc. outperform tech stocksTrend Reversal & Daily Chart Pattern Signals - خودرو بانک
Agios drops as FDA delays review of thalassemia drug - MSN
Can Agios Pharmaceuticals Inc. withstand a market correctionJuly 2025 Fed Impact & AI Enhanced Trading Signals - خودرو بانک
Agios Pharma stock faces FDA delay as PDUFA date extended for Pyrukynd - Investing.com Canada
AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia - Yahoo Finance
Backtesting results for Agios Pharmaceuticals Inc. trading strategiesTrade Volume Report & High Conviction Buy Zone Picks - Newser
FDA extends review period for Agios’ thalassemia drug By Investing.com - Investing.com Canada
Detecting support and resistance levels for Agios Pharmaceuticals Inc.Recession Risk & Weekly High Return Forecasts - Newser
Combining machine learning predictions for Agios Pharmaceuticals Inc.Market Trend Summary & Risk Managed Trade Strategies - Newser
How institutional ownership impacts Agios Pharmaceuticals Inc. stockWeekly Profit Report & Weekly Consistent Profit Watchlists - Newser
Will Agios Pharmaceuticals Inc. stock recover after recent dropMarket Sentiment Summary & Consistent Growth Equity Picks - Newser
Liver Injury REMS Delays Agios’s Pyrukynd US FDA Approval In Thalassemia - insights.citeline.com
Agios Pharma stock falls as BofA lowers price target on PDUFA delay - Investing.com Canada
Agios Pharma stock faces FDA delay as PDUFA date extended for thalassemia drug - Investing.com Canada
Agios Pharmaceuticals: New FDA Setback Likely Temporary As Issues Can Be Mitigated - Seeking Alpha
Agios Pharma Stock Slumped 15% Today But Company Remains Top Pick For This Analyst – Find Out More - Stocktwits
FDA Delays Decision On Agios Pharmaceuticals' Blood Disorder Drug For Expanded Use - Benzinga
Agios Pharmaceuticals shares fall 13.52% intraday after FDA delays PDUFA target date for PYRUKYND. - AInvest
FDA delays decision on Agios drug in thalassemia over liver safety - Endpoints News
Why Did Agios Plunge 26.94%? FDA Delays PYRUKYND Review - AInvest
Agios Pharmaceuticals and the FDA Delay for Pyrukynd in Thalassemia: Assessing the Materiality of Safety Concerns and REMS Submission on Commercial Potential and Stock Valuation - AInvest
Agios stock drops as FDA delays Pyrukynd review (AGIO:NASDAQ) - Seeking Alpha
FDA extends review period for Agios’ thalassemia drug - Investing.com
Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia - The Manila Times
FDA Extends Review of First Oral Treatment for Thalassemia: Agios' PYRUKYND Decision Set for December - Stock Titan
Is Agios Pharmaceuticals Inc. stock ready for a breakout2025 Analyst Calls & Trade Opportunity Analysis Reports - Newser
Is Agios Pharmaceuticals Inc. trending in predictive chart models2025 AllTime Highs & Daily Volume Surge Trade Alerts - Newser
Price momentum metrics for Agios Pharmaceuticals Inc. explainedIPO Watch & Free Growth Oriented Trading Recommendations - Newser
Should you hold or exit Agios Pharmaceuticals Inc. nowJuly 2025 EndofMonth & Real-Time Volume Triggers - Newser
Is Agios Pharmaceuticals Inc. still worth holding after the dip2025 Market WrapUp & AI Based Buy and Sell Signals - Newser
Full technical analysis of Agios Pharmaceuticals Inc. stockTrade Volume Summary & Verified Swing Trading Watchlist - Newser
How to forecast Agios Pharmaceuticals Inc. trends using time seriesM&A Rumor & Fast Entry Momentum Alerts - Newser
Is Agios Pharmaceuticals Inc. undervalued by DCF analysisMarket Sentiment Review & Reliable Momentum Entry Alerts - خودرو بانک
Should you wait for a breakout in Agios Pharmaceuticals Inc.2025 Retail Activity & Fast Exit Strategy with Risk Control - Newser
Price action breakdown for Agios Pharmaceuticals Inc.Portfolio Value Summary & High Yield Stock Recommendations - Newser
Long term hold vs stop loss in Agios Pharmaceuticals Inc.Treasury Yields & Daily Chart Pattern Signal Reports - Newser
What MACD signals say about Agios Pharmaceuticals Inc.Weekly Stock Recap & Technical Buy Zone Confirmations - Newser
Developing predictive dashboards with Agios Pharmaceuticals Inc. dataIndex Update & Fast Momentum Entry Tips - Newser
Historical volatility pattern of Agios Pharmaceuticals Inc. visualizedEarnings Growth Summary & Daily Technical Forecast Reports - Newser
Chart Patterns Forming a Bullish Setup in Agios Pharmaceuticals Inc.Sell Signal & Free High Return Stock Watch Alerts - beatles.ru
Can trapped investors hope for a rebound in Agios Pharmaceuticals Inc.Trade Volume Report & Weekly Stock Breakout Alerts - Newser
How to track smart money flows in Agios Pharmaceuticals Inc.July 2025 Snapshot & Capital Efficient Trading Techniques - Newser
Can Agios Pharmaceuticals Inc. deliver consistent EPS growthWeekly Stock Recap & Weekly High Return Stock Opportunities - خودرو بانک
Is Agios Pharmaceuticals Inc. a turnaround storyJuly 2025 Summary & High Accuracy Investment Entry Signals - خودرو بانک
Commit To Buy Agios Pharmaceuticals At $30, Earn 34.9% Annualized Using Options - Nasdaq
Using AI based signals to follow Agios Pharmaceuticals Inc.Quarterly Trade Review & High Accuracy Trade Alerts - Newser
What moving averages say about Agios Pharmaceuticals Inc.Watch List & Safe Capital Investment Plans - Newser
Long term hold vs stop loss in Agios Pharmaceuticals Inc2025 Biggest Moves & Daily Stock Trend Watchlist - Newser
Will Agios Pharmaceuticals Inc. benefit from sector rotation2025 Buyback Activity & AI Powered Market Entry Ideas - خودرو بانک
Earnings Beat: Does Agios Pharmaceuticals Inc. outperform in volatile marketsCPI Data & Daily Risk Controlled Trade Plans - خودرو بانک
1.40%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):